medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 6

<< Back Next >>

Ann Hepatol 2013; 12 (6)

Percutaneous liver biopsy – 2 decades of experience in a public hospital in the South of Brazil

Bergesch DR, Campos ASM, Lerias APR, Plasse RV, Valle TC

Language: English
References: 29
Page: 876-880
PDF size: 80.85 Kb.


ABSTRACT

Introduction. Liver biopsy is a complementary method for diagnosis, staging and therapeutic guidance in liver diseases, where chronic viral hepatitis are the most acknowledged causes for the indication of histopathological study. The objective is to assess the patients’ profile as well as the indication and results of percutaneous liver biopsies in a tertiary hospital. Material and methods. A descriptive, cross-section study was carried out through the review of medical charts (retrospective cohort) of patients submitted to blind percutaneous liver biopsies (PLB) at a hospital in Porto Alegre, South Brazil, from October 1993 to December 2011. Results. 1,955 PLB were carried out, the mean patients’ age was 44.8 years old, and 1,127 (57.65%) were men. Chronic hepatitis C was the main indication (60.5%), followed by HCV-HIV coinfection (12.2%) and chronic hepatitis B (3.5%). Seven cases (0.3%) had complications, without deaths. Conclusion. PLB is a safe method and continues to be an important option to assist patients with chronic liver disease.


REFERENCES

  1. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. AASLD Position Paper. Liver biopsy. Hepatology 2009; 49: 1017-44.

  2. Lembrança L, Medina J, Portugal M, Gadelha R, de Freitas LA, Paraná R. Epidemiological assesment of liver disease in Northeastern Brazil by means of a standardized liver biopsy protocol. Ann Hepatol 2011; 10: 43-9.

  3. D’Souza RFC, Feakins R, Mears L, Sabin CA, Foster GR. Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C. Aliment Pharmacol Ther 2005; 21: 519-24.

  4. Malik AH, Kumar KS, Malet PF, Jain R, Prasad P, Ostapowicz G.Correlation of percutaneous liver biopsy fragmentation and degree of liver fibrosis. Aliment Pharmacol Therap 2004; 19:545-9.

  5. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the group of epidemiology of the French Association of the Study of the Liver (AFEF). Hepatology 2000; 32: 477-81.

  6. Farrel RJ, Smiddy PF, Pilkington RM, Tobin AA, Mooney EE, Temperley IJ, McDonald GS, et al. Guided versus blind liver biopsy for chronic hepatitis C: clinical benefits and costs. J Hepatol 1999; 30: 580-7.

  7. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de DST, Aids e Hepatites Virais. Protocolo Clínico e Diretrizes Terapêuticas para Hepatite Viral B e Coinfecções. Brasília, Ministério da Saúde, 2010. 132 p. Série A. Normas e Manuais Técnicos. In: http://portal.saude.gov.br/portal/arquivos/ pdf/prot_clinico_diretrizes_terapeuticas_hep_b.pdf

  8. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de DST, Aids e Hepatites Virais. Protocolo Clínico e Diretrizes Terapêuticas para Hepatite Viral C e Coinfecções. Brasília, Ministério da Saúde, 2011. 144 p. Série A. Normas e Manuais Técnicos. In: http://portal.saude.gov.br/portal/arquivos/ pdf/prot_clinico_diretrizes_tera_hepatite_c.pdf

  9. Sherlock S. Biopsy of the liver. In: Sherlock S, Dooley J (eds.). Diseases of the liver and biliary system. 10th ed. 1998, p. 33-41.

  10. Bedossa P, Poynard T. METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.

  11. Grant A, Neuberger J. Guidelines on the use of liver biopsy in the clinical practice. Gut 1999; 45 (Suppl. IV): IV1–IV11.

  12. Almeida PRL, Tovo CV, Oliveira JF, Santos GC, Santos AP, Souza AR. Biópsia Hepática percutânea: estudo de 1037 casos. GED. Gastroenterologia e Endoscopia 2004; 23: 221-6.

  13. Cadranel JFD, Nousbaum JB, Hanslik B. Major trends in liver biopsy in France: results of a nationwide 2009 survey. AASLD abstracts. Hepatology 2012; 1096A.

  14. Focaccia R, Baraldo DC, Ferraz ML, Martinelli AL, Carrilho FJ, Gonçales FL Jr, Pedroso ML, et al. Demographic and anthropometrical analysis and genotype distribuition of chronic hepatitis C Patients Treated in public and private reference centers in Brazil. Braz J Infect Dis 2004; 8: 348-55.

  15. Enjoji M, Kohjima M, Kotoh K, Nakamuta M. Metabolic Disorders and Steatosis in Patients with Chronic Hepatitis C:Metabolic Strategies for Antiviral Treatments. Int J Hepatol 2012; 2012: 264017.

  16. Tovo CV, Mattos AA, Souza AR, Ferrari de Oliveira Rigo J, Lerias de Almeida PR, Galperim B, Riegel Santos B. Impact of human immunodeficiency vírus infection in patients infected with the hepatitis C virus. Liver International 2007; 27: 40-6.

  17. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.

  18. Costa LB, Ferraz ML, Perez RM, Ferreira AS, Matos CA, Lanzoni VP, Silva AE. Effect of host-related factors on the intensity of liver fibrosis in patients with chronic hepatitis C virus infection. Braz J Infect Dis 2002; 6: 219-24.

  19. Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C, Pradat P, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003; 52: 574-9.

  20. Patel A, Harrison SA. Hepatitis C virus infection and nonalcoholic steatohepatitis. Gastroenterology & Hepatology 2012; 8: 305-12.

  21. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in Chronic Hepatitis C: Why does it really matter? Gut 2006; 55: 123-30.

  22. Bugianesi E, Salamone F, Negro F. The interaction of metabolic factors with HCV infection: does it matter? J Hepatol 2012; 56(S1): S56-S65.

  23. Price JC, Thio CL. Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol 2010; 8: 1002-12.

  24. Crum-Cianflone N, Dilay A, Collins G, Asher D, Campin R, Medina S, Goodman Z, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009; 50: 464-73.

  25. Guyader D, Thirouard AS, Erdtmann L, Rakba N, Jacquelinet S, Danielou H, Perrin M, et al. Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 587-95.

  26. Girelli D, Pasino M, Goodnough JB, Nemeth E, Guido M, Castagna A, Busti F, et al. Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol 2009; 51: 845-52.

  27. Guyader D, Thirouard AS, Erdtmann L, Rakba N, Jacquelinet S, Danielou H, Perrin M, et al. Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. J Hepatol 2007; 6: 587-95.

  28. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997; 25: 759-68.

  29. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy: a multicenter retrospective study on 68,276 biopsies. J Hepatol 1986; 2: 165-73.




2020     |     www.medigraphic.com